Omeros Co. (OMER) Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Omeros Co. (NASDAQ:OMER) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 516,632 shares of the biopharmaceutical company’s stock after acquiring an additional 35,974 shares during the period. Geode Capital Management LLC owned 1.05% of Omeros worth $5,755,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers grew its holdings in Omeros by 73.3% during the 4th quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock worth $805,000 after acquiring an additional 30,547 shares during the period. Man Group plc acquired a new stake in Omeros during the 3rd quarter worth about $286,000. Sheaff Brock Investment Advisors LLC grew its holdings in Omeros by 8.8% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 24,750 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 2,000 shares during the period. BlackRock Inc. grew its holdings in Omeros by 1.0% during the 3rd quarter. BlackRock Inc. now owns 3,957,936 shares of the biopharmaceutical company’s stock worth $96,614,000 after acquiring an additional 38,349 shares during the period. Finally, Vanguard Group Inc grew its holdings in Omeros by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 2,204,427 shares of the biopharmaceutical company’s stock worth $53,810,000 after acquiring an additional 34,043 shares during the period. Hedge funds and other institutional investors own 49.28% of the company’s stock.

Shares of OMER opened at $18.52 on Friday. The stock has a market capitalization of $907.70 million, a PE ratio of -8.34 and a beta of 3.60. Omeros Co. has a one year low of $10.30 and a one year high of $27.00.

Omeros (NASDAQ:OMER) last issued its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.37. The firm had revenue of $22.02 million during the quarter, compared to analyst estimates of $22.42 million. The business’s quarterly revenue was up 60.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.34) earnings per share. Analysts anticipate that Omeros Co. will post -0.3 earnings per share for the current year.

A number of brokerages have weighed in on OMER. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a report on Friday, March 1st. ValuEngine upgraded Omeros from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Omeros in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. Omeros presently has an average rating of “Buy” and an average price target of $27.00.

TRADEMARK VIOLATION WARNING: “Omeros Co. (OMER) Holdings Increased by Geode Capital Management LLC” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2019/04/21/omeros-co-omer-holdings-increased-by-geode-capital-management-llc.html.

Omeros Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Article: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.